Hunter Land

RESEARCH & DEVELOPMENT

Hunter Land, MS, PhD, is the Vice President of Research & Development at Biopharmaceutical Research Company. He has more than 18 years of expertise across 25 different indications, as well as 11 years of cannabinoid-focused research. As an expert in the field of cannabinoid science, he has developed a pipeline of discovery work on over 20 novel cannabinoids and terpenes. Previously, Hunter acted as the Sr. Scientific Director, Director of Cannabinoid Research, and scientific spokesperson at Canopy Growth Corporation, the world’s largest cannabis producer. Most notably, Hunter was GW Pharma’s first full time employee within in the US, where he co-authored multiple protocols in refractory epilepsy (Dravet Syndrome and Lennox-Gastaut Syndrome), Multiple Sclerosis, pain, and was closely involved in the development of Epidiolex® (FDA approved prescription CBD) and Sativex®. He has been a speaker at over 50 scientific conferences, a named inventor on 6 patent applications, has over 20 publications, is a guest lecturer at the University of Wisconsin and University of Colorado Skaggs School of Pharmacy.